J. Stassen

发表

Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.

G. Matthyssens, P. Holvoet, D. Collen, 1991, The Journal of biological chemistry.

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993 .

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993, Blood.

On the Immunogenicity of Recombinant Staphylokinase in Patients and in Animal Models

D. Collen, J. Stassen, S. Vanderschueren, 1994, Thrombosis and Haemostasis.

Vascular wound healing and neointima formation induced by perivascular electric injury in mice.

P. Carmeliet, J. J. van den Oord, L. Moons, 1997, The American journal of pathology.

platelet-rich femoral vein thrombosis model hamster N-(mercaptoacetyl)-D-Tyr-Arg- Gly-Asp-sulfoxide (G4120) in a Antithrombotic properties of L-cysteine,

S. Bunting, D. Collen, F. Stockmans, 2011 .

Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.

S. Bunting, D. Collen, F. Stockmans, 1992, Blood.

Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog

B. Keyt, H. Gold, T. Roskams, 1994, Thrombosis and Haemostasis.

Biological Effects of Inactivation of the Genes for Tissue-type Plasminogen Activator, Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Mice

P. Carmeliet, R. Bronson, L. Kieckens, 1993 .

Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits

C. Korninger, D. Collen, J. Stassen, 1981, Thrombosis and Haemostasis.

Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.

M. Hoylaerts, D. Collen, J. Stassen, 1995, Circulation.

Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.

H. Gold, T. Roskams, R. Kiss, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – III. Thrombolytic Properties of Natural and Recombinant Urokinase in Rabbits with Experimental Jugular Vein Thrombosis

M. Blaber, M. Verstraete, D. Collen, 1984, Thrombosis and Haemostasis.

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

P. Carmeliet, J. J. van den Oord, R. Mulligan, 1993, The Journal of clinical investigation.

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.

M. Verstraete, D. Collen, J. Stassen, 1983, The Journal of clinical investigation.

collagen, prevents platelet-rich thrombosis in hamsters Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to

H. Deckmyn, J. Vermylen, E. V. Houtte, 2011 .

Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters.

H. Deckmyn, J. Vermylen, J. Stassen, 1995, Blood.

Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis

D. Collen, H. Lijnen, J. Stassen, 1991 .

In vivo studies of a synthetic inhibitor of thrombin.

E. Shaw, O. Matsuo, D. Collen, 1982, The Journal of laboratory and clinical medicine.

Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.

H. Deckmyn, J. Vermylen, H. Matsuno, 1994, Circulation.

Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator

D. Collen, I. Juhan-vague, M. Alessi, 1987, Thrombosis and Haemostasis.

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

C. Korninger, O. Matsuo, D. Collen, 1982, The Journal of clinical investigation.

Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.

T. Quertermous, M. Dewerchin, M. Ginsberg, 1991, Blood.

Vascular endothelial growth factor receptor 1 expression in nasal polyp tissue

P. Carmeliet, C. Bachert, P. Hellings, 2014, Allergy.

Thrombus imaging with an I-123-labeled F(ab')2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model.

J. Melin, D. Collen, J. Stassen, 1989, Radiology.

Antagonism of vWF Inhibits both Injury Induced Arterial and Venous Thrombosis in the Hamster

J. Vermylen, M. Hoylaerts, H. Yamamoto, 1998, Thrombosis and Haemostasis.

Characterisation of a Novel Series of Aprotinin-Derived Anticoagulants

J. Vermylen, J. Sixma, A. Lambeir, 1995, Thrombosis and Haemostasis.

Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.

D. Pennica, D. Collen, W. Bennett, 1984, The Journal of pharmacology and experimental therapeutics.

Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators

L. Nelles, H. Lijnen, D. Collen, 1991, Circulation.

Synergism of thrombolytic agents in vivo.

M. Verstraete, D. Collen, J. Stassen, 1986, Circulation.

mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 )

L. Nelles, D. Collen, H. Lijnen, 2003 .

Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.

L. Nelles, D. Collen, H. Lijnen, 1992, Blood.

Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits.

D. Collen, H. Bounameaux, J. Stassen, 1986, Blood.

Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys.

M. Colucci, D. Collen, J. Stassen, 1984, The Journal of clinical investigation.

Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.

D. Collen, J. Stassen, D. Spriggs, 1989, Blood.

Inhibitory Effect of Piracetam on Platelet-rich Thrombus Formation in an Animal Model

H. Deckmyn, J. Vermylen, F. Stockmans, 1998, Thrombosis and Haemostasis.

In Vivo Models For Experimental Thrombolysis

D. Collen, J. Stassen, 1993 .

Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.

G. Larsen, D. Collen, J. Stassen, 1988, Blood.

Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.

D. Collen, J. Stassen, Y. Imura, 1992, The Journal of pharmacology and experimental therapeutics.

Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits.

D. Collen, H. Bounameaux, J. Stassen, 1986, Blood.

Identification of plasminogen activator releasing activity in the neurohypophysis

M. Colucci, D. Collen, J. Stassen, 1984, British journal of haematology.

Prolonged Inhibition of Acute Arterial Thrombosis by High Dosing of a Monoclonal Anti-platelet Glycoprotein IIb/IIIa Antibody in a Baboon Model

H. Deckmyn, J. Vermylen, S. Lamprecht, 1995, Thrombosis and Haemostasis.

Binding Properties of Monoclonal Antibodies against Human Fragment D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model in Rabbits

P. Holvoet, D. Collen, J. Stassen, 1989, Thrombosis and Haemostasis.

213 Thrombus imaging with 123I-labeled Fab fragments of two fibrin fragment D-dimer specific antibodies in a rabbit model of venous thrombosis

P. Holvoet, D. Collen, J. Stassen, 1988 .

Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase

P. Declerck, H. Lijnen, D. Collen, 1992 .

combinations in venous thrombosis models in dogs and rabbits single-chain urokinase-type plasminogen activator, and synergistic Thrombolytic properties of human tissue-type plasminogen activator,

D. Collen, J. Stassen, D. Spriggs, 2013 .

Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.

P. Carmeliet, R. S. Meidell, R. Gerard, 1997, Blood.

Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-12 of α2-antiplasmin (fibrin cross-linking site) and amino aids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator

H. Nakamura, D. Collen, H. Lijnen, 1992 .

Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.

D. Collen, H. Lijnen, J. Stassen, 1991, Blood.

Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits

D. Collen, J. Stassen, D. Spriggs, 1989 .

Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice

P. Carmeliet, R. S. Meidell, R. Gerard, 1994 .

Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase

A. Vandamme, M. Dewerchin, P. Holvoet, 1992, Thrombosis and Haemostasis.

A Historical Review of Hemostasis, Thrombosis, and Antithrombotic Therapy

J. Stassen, J. Stassen, Å. Nyström, 1997, Annals of plastic surgery.

Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions.

M. Hoylaerts, H. Deckmyn, J. Vermylen, 1995, Blood.

Characterisation of a Novel Series of Aprotinin-derived Anticoagulants

H. Deckmyn, J. Vermylen, G. Matthyssens, 1995, Thrombosis and Haemostasis.

The hemostatic system.

H. Deckmyn, J. Arnout, H Deckmyn, 2004, Current medicinal chemistry.

A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons

P. Verhamme, J. Saint-Remy, M. Jacquemin, 2009, Journal of thrombosis and haemostasis : JTH.

Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin

L. Kieckens, M. Dewerchin, D. Collen, 1989 .

Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.

D. Collen, J. Stassen, E. Demarsin, 1987, Blood.

Dose-responses to inducers and inhibitors of platelet aggregation analysed via a micro-method.

M. Hoylaerts, J. Vermylen, C. Thys, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Induction of t-PA Synthesis with intravenous bolus injection of vitamin A palmitate in vitamin a deficient rats

L. Nelles, P. Declerck, H. Moreau, 1992 .

A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents

D. Collen, H. Lijnen, J. Stassen, 1990 .

Arterial neointima formation after trauma in mice with inactivation of the t-PA, u-PA or PAI-1 genes

P. Carmeliet, C. Declercq, D. Collen, 1994 .

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

L. Moons, D. Collen, S. Janssens, 1996, Circulation.

Isolation and conditioning of recombinant staphylokinase for use in man

D. Collen, M. Mol, J. Stassen, 1993 .

Receptor-independent plasminogen activation by urokinase-type plasminogen activator promotes, and adenoviral pai-1 gene transfer inhibits arterial neointima formation in mice

P. Carmeliet, C. Declercq, L. Moons, 1996 .

Fast and Reproducible Vascular Neointima Formation in the Hamster Carotid Artery: Effects of Trapidil and Captopril

M. Hoylaerts, H. Deckmyn, J. Vermylen, 1995, Thrombosis and Haemostasis.

human tissue-type plasminogen activator in rabbits Pharmacokinetics and thrombolytic properties of deletion mutants of

G. Larsen, D. Collen, J. Stassen, 2011 .

in a hamster pulmonary embolism model continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator Comparative thrombolytic properties of bolus injections and

D. Collen, H. Lijnen, J. Stassen, 2011 .

Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line

D. Collen, H. Lijnen, B. van Hoef, 1992, Thrombosis and Haemostasis.

Synergistic Effect on Thrombolysis of Sequential Infusion of Tissue-Type Plasminogen Activator (t-PA) Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) and Urokinase in the Rabbit Jugular Vein Thrombosis Model

D. Collen, J. Stassen, F. De cock, 1987, Thrombosis and Haemostasis.

Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model

L. Nelles, L. Kieckens, D. Collen, 1991, Thrombosis and Haemostasis.

Thrombolytic Properties Of Purified Human Tissue Plasminogen Activator In A Dog Femoral Vein Thrombosis Model

C. Korninger, O. Matsuo, D. Collen, 1981, Thrombosis and Haemostasis.

Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons

D. Collen, H. Lijnen, J. Stassen, 1992 .

D. Collen, H. Lijnen, J. Stassen, 1992, Blood.

Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.

M. Dewerchin, D. Collen, H. Lijnen, 1990, Circulation.

Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.

D. Collen, J. Stassen, S. Vanderschueren, 1996, Journal of cardiovascular pharmacology.

Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.

D. Collen, P. Holvoet, J. Van Cleemput, 1998, Arteriosclerosis, thrombosis, and vascular biology.

COMPARATIVE THROMBOLYTIC PROPERTIES OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (RT-PA) AND OF 2 PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) RESISTANT GLYCOSYLATION VARIANTS IN A COMBINED ARTERIAL AND VENOUS THROMBOSIS MODEL IN THE DOG

T. Roskams, R. Lijnen, I. Jang, 1993 .

ANTITHROMBOTIC PROPERTY OF G4120, A CYCLIC ARG-GLY-ASP CONTAINING PEPTIDE, IN A HAMSTER PLATELET-RICH FEMORAL VEIN-THROMBOSIS MODEL

S. Bunting, D. Collen, F. Stockmans, 1991 .

Combination of animal models and biotechnologies in the development of new thrombolytic agents

D. Collen, H. Lijnen, J. Stassen, 1993 .